30 closest matches · ranked by relevance
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Desmoid Tumors · Aggressive Fibromatosis
Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants
Desmoid Tumor
Primary: Percentage of Patients Failure Free at 2 Years Following Study Entry — 36 percentage of participants
Desmoid Tumor · Aggressive Fibromatosis
Primary: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. — NA; 15.1 Months — p=< 0.001
Desmoid Tumor
Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63
Dermatofibrosarcoma Protuberans
Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Dupuytren's Disease
Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants
Gastro Intestinal Stromal Tumor
Primary: Time to Next Treatment (TNT) — 26.7 months
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
Adenomatous Polyposis Coli
Primary: Change in Marked Polyp Size — 16; 4; 0 Size of marked polyps
Rectal Cancer
Primary: Correlation Between Ploidy Status With Local Recurrence of Cancer — 3; 31; 14; 92 Participants
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
GIST
Primary: Number of Participants With a Clinical Activity-radiographic Response — 0; 0; 0; 0 Participants
Familial Adenomatous Polyposis
Primary: Number of Subjects With Any FAP-related Event. — 18; 23; 22; 2 Participants — p=0.1210
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Cowden's Disease · Hamartoma Syndrome, Multiple
Primary: Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.
Lipoma
Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
Familial Adenomatous Polyposis
Primary: Number of Polyps — 18.6; 22.6 Number of Polyps
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Soft Tissue Sarcoma
Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs
Adult Fibrosarcoma · Adult Leiomyosarcoma · Adult Liposarcoma
Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Acromegaly
Primary: Effect of Pegvisomant on Colon Tissue p53 Expression — 330.57 ng/mL
Carney Complex · Chondrosarcoma · Gastrointestinal Stromal Tumor
Primary: Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1 — 0 participants